Pharmacokinetic and pharmacodynamic profiling of four antimicrobials against Acinetobacter baumannii infection
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 138, 103809
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Liaoning Province
This publication has 37 references indexed in Scilit:
- Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with TigecyclineAntimicrobial Agents and Chemotherapy, 2012
- Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of PatientsAntimicrobial Agents and Chemotherapy, 2011
- Worldwide Dissemination of the bla OXA-23 Carbapenemase Gene of Acinetobacter baumannii 1 Emerging Infectious Diseases, 2009
- Antimicrobial Resistance:Acinetobacter baumannii:Epidemiology, Antimicrobial Resistance, and Treatment OptionsClinical Infectious Diseases, 2008
- Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004International Journal of Antimicrobial Agents, 2007
- Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast EnglandJournal of Clinical Microbiology, 2006
- The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin‐Structure Infections: Results of 2 Double‐Blind Phase 3 Comparison Studies with Vancomycin‐AztreonamClinical Infectious Diseases, 2005
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'Nature Reviews Microbiology, 2004